May 15 |
Exploring Three Swedish Growth Companies With High Insider Ownership On The Swedish Exchange
|
May 14 |
Calliditas Therapeutics: Everest Medicines launches Nefecon in China
|
May 14 |
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
|
May 6 |
Calliditas releases phase 2 results on head and neck cancer asset setanaxib
|
May 6 |
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
|
May 2 |
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Apr 24 |
Calliditas Therapeutics' 2023 Annual Report Published
|
Apr 24 |
Calliditas Announces Positive NefIgArd Open Label Extension Results
|
Apr 18 |
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
|